title: [Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma providing a good QOL].
abstract: We report a case of advanced hepatocellular carcinoma (HCC). A 73-year-old man with positive HBV and HCV underwent a partial hepatectomy (S6 and S5) twice and transcatheter arterial (chemo) embolization (TAE) four times, thereafter. During these treatments, HCC became intractable and the patient complained of general fatigue. The liver function was Child's classification A, and serum AFP was 6,737 ng/ml. Abdominal CT scan revealed recurrent lesions in the right hepatic lobe and left adrenal gland. The catheter for hepatic arterial infusion chemotherapy was inserted from the left femoral artery. Arterial chemotherapy with 5-fluorouracil (5-FU 750 mg) and cisplatin (CDDP 10 mg) was performed every two weeks. During 6 courses of this regimen, a significant side effect did not appear. Abdominal CT revealed no change in size, but serum AFP decreased up to 794 ng/ml and the general fatigue subsided. After 2 months, serum AFP began to increase and became 1454 ng/ml. The regimen of arterial chemotherapy was changed to epirubicin (EPI 40 mg every two weeks) and UFT-E (300 mg/day for four weeks), followed by a week off. An appetite loss (grade 2) appeared, but it could be well controlled. Serum AFP decreased again, up to 54 ng/ml. A good QOL was kept for about one year after the initiation of hepatic arterial infusion chemotherapy.
authors.affiliation: Dept. of Surgery, Nishinomiya Municipal Central Hospital.
authors.forename: Shinya
authors.initials: S
authors.lastname: Yamashita
authors.forename: Takahiro
authors.initials: T
authors.lastname: Niinobu
authors.forename: Sumiko
authors.initials: S
authors.lastname: Nakagawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Amano
authors.forename: Yasuaki
authors.initials: Y
authors.lastname: Nishikawa
authors.forename: Hirohito
authors.initials: H
authors.lastname: Hayashida
authors.forename: Naozumi
authors.initials: N
authors.lastname: Higaki
authors.forename: Makoto
authors.initials: M
authors.lastname: Fujita
authors.forename: Masato
authors.initials: M
authors.lastname: Sakon
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000628:therapy; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006498:Hepatectomy; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D011788:Quality of Life; D005641:Tegafur; D014057:Tomography, X-Ray Computed; D014498:Uracil; D000509:alpha-Fetoproteins / Q000032:analysis
chemical_list: D000509:alpha-Fetoproteins; D005641:Tegafur; D015251:Epirubicin; D014498:Uracil; D002945:Cisplatin; D005472:Fluorouracil